Medtronic received information via literature regarding outcomes following stentless bioprosthesis implant in patients with infective endocarditis of the aortic valve with root destruction.All data was collected from a single center between june 2000 and december 2014.The study population included 54 patients (predominantly male; mean age 61 years), all of which were implanted with a medtronic freestyle valve (serial numbers were not provided).The literature reported 13 deaths which occurred due to: myocardial infarction (mi), multi-organ failure, left ventricle failure, right ventricle failure, respiratory insufficiency, intestinal ischemia, congestive heart failure (chf), sepsis, urosepsis, lymphoma, and pancreatic cancer.One patient was reported to expire from postanoxic encephalopathy following cardiac arrest.Based on the available information, none of the deaths were attributed to a medtronic product.Among all patient¿s adverse events included: mild aortic regurgitation, elevated gradients, 6 renal failure, 5 patients required reoperation for bleeding, and 13 required permanent pacemaker implant.One case of recurrent postoperative endocarditis was reported 2.3 years following.The infection grew a pneumococcus strain which involved the left main coronary artery, roof of the left atrium, left atrial appendage and anterior mitral valve leaflet.Subsequently, the patient required reconstruction with a second freestyle valve implant.The patient was prescribed antibiotic therapy and recovered.No additional adverse patient effects were reported.
|